142 research outputs found
New Jurassic amber outcrops from Lebanon
International audienceAmber predating the Lower Cretaceous is extremely rare. During the past two decades, records of discoveries of amber sites have increased considerably worldwide. We report herein the discovery of ten new outcrops of amber from the Late Jurassic in Lebanon, in addition to other nine outcrops described by Azar et al. (2010). Some of these outcrops gave large centimetric sized amber pieces. Each of these new amber outcrops is described, and its infrared spectrum is given. Though the Jurassic amber yielded to date no more than some fungal inclusions, this discovery is significant and promising especially in the reconstruction of the paleoenvironment
Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life
Background. Protein-energy wasting is a frequent and debilitating condition in maintenance dialysis. We randomly tested if an energy-dense, phosphate-restricted, renal-specific oral supplement could maintain adequate nutritional intake and prevent malnutrition in maintenance haemodialysis patients with insufficient intake. Methods. Eighty-six patients were assigned to a standard care (CTRL) group or were prescribed two 125-ml packs of Renilon 7.5® daily for 3 months (SUPP). Dietary intake, serum (S) albumin, prealbumin, protein nitrogen appearance (nPNA), C-reactive protein, subjective global assessment (SGA) and quality of life (QOL) were recorded at baseline and after 3 months. Results. While intention to treat analysis (ITT) did not reveal strong statistically significant changes in dietary intake between groups, per protocol (PP) analysis showed that the SUPP group increased protein (P < 0.01) and energy (P < 0.01) intakes. In contrast, protein and energy intakes further deteriorated in the CTRL group (PP). Although there was no difference in serum albumin and prealbumin changes between groups, in the total population serum albumin and prealbumin changes were positively associated with the increment in protein intake (r = 0.29, P = 0.01 and r = 0.27, P = 0.02, respectively). The SUPP group did not increase phosphate intake, phosphataemia remained unaffected, and the use of phosphate binders remained stable or decreased. The SUPP group exhibited improved SGA and QOL (P < 0.05). Conclusion. This study shows that providing maintenance haemodialysis patients with insufficient intake with a renal-specific oral supplement may prevent deterioration in nutritional indices and QOL without increasing the need for phosphate binder
Nouveaux gisements fossilifères à Charophytes barrémiens dans les "Grès du Liban" auct. (Liban), avec un point de vue critique sur la nature de Munieria Deecke, 1883
The "Grès du Liban" auct. is the thick basal unit of the Lower Cretaceous series in Lebanon. There are two key levels in this dominantly siliciclastic unit: the "Banc de Mréjatt" and the "Calcaire à pisolithes", the latter of which includes limestones and marls with Charophyta. The rich charophyte assemblage described by Grambast and Lorch (1968) from a site near Jezzine is Barremian (possibly Early Barremian) in age, not Bedoulian as previously stated. Besides gyrogonites and utricles, charophyte thalli are rather common; they are ascribed to two organ genera, Munieria Deecke, 1883, and Charaxis Harris, 1939. Based on topotypic material (from the Pia Collection), Munieria baconica Deecke, 1883, the type-species of the genus, is reassessed. In addition, the species Clypeina parvula Carozzi, 1946, is transferred to the revised genus Munieria, and a new species of Charaxis is described.Les "Grès du Liban" auct. constituent l'épaisse unité à la base des séries du Crétacé inférieur au Liban. Il y a deux niveaux-repères dans cette unité essentiellement silicoclastique : le "Banc de Mréjatt" et le "Calcaire à pisolithes" ; ce dernier comporte des passées calcaires ou marneuses à Charophytes. La riche association de Charophytes décrite par Grambast et Lorch (1968) comme provenant d'un site proche de Jezzine est d'âge barrémien (peut-être Barrémien inférieur) et non bédoulien comme cela était indiqué précédemment. À côté des gyrogonites et des utricules, les thalles de Charophytes sont plutôt communs ; ils sont attribués à deux genres d'organes, Munieria Deecke, 1883, et Charaxis Harris, 1939. Sur la base de matériel topotypique (provenant de la Collection Pia), Munieria baconica Deecke, 1883, l'espèce-type du genre, est réexaminée. Pour compléter cette étude, nous transférons l'espèce Clypeina parvula Carozzi, 1946, dans le genre Munieria révisé et décrivons une nouvelle espèce du genre Charaxis
Avancées dans une réécriture de l'histoire de la transition du Jurassique au Crétacé dans le Mont Liban
The stratigraphic framework of the Upper Jurassic and Lower Cretaceous strata of Lebanon that dates back to Dubertret's publications required either consolidation or full revision. The preliminary results of our investigations in the Mount Lebanon region are presented here. We provide new micropaleontological and sedimentological information on the Salima Oolitic Limestones, which is probably an unconformity-bounded unit (possibly Early Valanginian in age), and the "Grès du Liban" (Barremian in age). Our revised bio- and holostratigraphic interpretations and the new age assignations lead us to emphasize the importance of the two hiatuses in the sedimentary record below and above the Salima, i.e., at the transition from the Jurassic to the Cretaceous.Le canevas stratigraphique du Jurassique supérieur et du Crétacé inférieur du Liban date des publications anciennes de Dubertret et aurait donc besoin d'être soit toiletté et consolidé, soit révisé de fond en comble. Les résultats préliminaires de nos recherches dans la région du Mont Liban sont exposés ici. Nous fournissons des données micropaléontologiques et sédimentologiques inédites sur les Calcaires oolithiques de Salima, qui constituent vraisemblablement une unité lithostratigraphique particulière, une "UBU", car encadrée par deux discontinuités (probablement d'âge Valanginien inférieur), et sur le Grès du Liban (d'âge barrémien). Nos nouvelles interprétations bio- et holostratigraphiques, ainsi que nos nouvelles attributions chronostratigraphiques, nous permettent de souligner l'importance des deux lacunes sédimentaires encadrant les Calcaires oolithiques de Salima, c'est-à -dire des lacunes significatives situées dans l'intervalle de transition du Jurassique au Crétacé
Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
Aim. The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin analogues (PGAs) and to determine the incidence of ocular surface disease in newly diagnosed, primary open-angle glaucoma (POAG) patients started on one of those 4 PGAs: bimatoprost (benzalkonium chloride, BAK, 0.3 mg/mL), latanoprost (BAK 0.2 mg/mL), travoprost (polyquad), and tafluprost (BAK-free). Patients and Methods. In this single-center, open-label trial, 32 patients newly diagnosed with POAG were randomly started on one of the four PGAs. All patients underwent a complete ophthalmological exam at presentation and at 1, 3, and 6 months of follow-up. Dry eye disease (DED) was assessed using the original Ocular Surface Disease Index (OSDI) questionnaire, in order to evaluate the impact of the drops on the quality of life of patients. Results. The mean age was 60.06 years ± 11.76. All four drugs equally and significantly reduced the intraocular pressure (IOP) with respect to the baseline IOP. There was a trend for a slightly greater reduction of IOP with bimatoprost, but the difference was not found to be statistically significant when compared to other PGAs. OSDI scores were significantly superior for travoprost (10.68 ± 5.73) compared to the other three drugs (p<0.05). Latanoprost caused the most significant eyelash growth and iris discoloration. Conjunctival hyperemia and superficial keratitis occurrence were similar in the four groups. Conclusion. All prostaglandin analogues equally and significantly reduce the IOP in patients with POAG. According to the results of the OSDI score, latanoprost seems to be the least tolerated among the four drugs
Advanced EFL learners' beliefs about language learning and teaching: a comparison between grammar, pronunciation, and vocabulary
This paper reports on the results of a study exploring learners’ beliefs on the learning and teaching of English grammar, pronunciation and vocabulary at tertiary level. While the importance of learners’ beliefs on the acquisition process is generally recognized, few studies have focussed on and compared learners’ views on different components of the language system. A questionnaire containing semantic scale and Likert scale items probing learners’ views on grammar, pronunciation and vocabulary was designed and completed by 117 native speakers of Dutch in Flanders, who were studying English at university. The analysis of the responses revealed that (i) vocabulary was considered to be different from grammar and pronunciation, both in the extent to which an incorrect use could lead to communication breakdown and with respect to the learners’ language learning strategies, (ii) learners believed in the feasibility of achieving a native-like proficiency in all three components, and (iii) in-class grammar, pronunciation and vocabulary exercises were considered to be useful, even at tertiary level. The results are discussed in light of pedagogical approaches to language teaching
Indicate separate contributions of long-lived and short-lived greenhouse gases in emission targets
European Union funding: 821205, 821003, 820829.
Wellcome Trust: 205212/Z/16/
Indicate separate contributions of long-lived and short-lived greenhouse gases in emission targets
Indicate separate contributions of long-lived and short-lived greenhouse gases in emission targets
European Union funding: 821205, 821003, 820829.
Wellcome Trust: 205212/Z/16/
The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2
Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701
- …